296 related articles for article (PubMed ID: 21437892)
1. Plasma Epstein-Barr virus DNA screening followed by ¹⁸F-fluoro-2-deoxy-D-glucose positron emission tomography in detecting posttreatment failures of nasopharyngeal carcinoma.
Wang WY; Twu CW; Lin WY; Jiang RS; Liang KL; Chen KW; Wu CT; Shih YT; Lin JC
Cancer; 2011 Oct; 117(19):4452-9. PubMed ID: 21437892
[TBL] [Abstract][Full Text] [Related]
2. Correlation of Epstein-Barr virus DNA in cell-free plasma, functional imaging and clinical course in locally advanced nasopharyngeal cancer: a pilot study.
Mäkitie AA; Reis PP; Irish J; Zhang T; Chin SF; Chen X; Marriott C; Keller A; Perez-Ordonez B; Kamel-Reid S; Siu LL
Head Neck; 2004 Sep; 26(9):815-22. PubMed ID: 15350028
[TBL] [Abstract][Full Text] [Related]
3. Comparison of plasma Epstein-Barr virus (EBV) DNA levels and serum EBV immunoglobulin A/virus capsid antigen antibody titers in patients with nasopharyngeal carcinoma.
Shao JY; Li YH; Gao HY; Wu QL; Cui NJ; Zhang L; Cheng G; Hu LF; Ernberg I; Zeng YX
Cancer; 2004 Mar; 100(6):1162-70. PubMed ID: 15022282
[TBL] [Abstract][Full Text] [Related]
4. [Prognostic impact of plasma Epstein-Barr virus DNA concentration on distant metastasis in nasopharyngeal carcinoma].
Hou X; Zhang L; Zhao C; Li S; Lu LX; Han F; Shao JY; Huang PY
Ai Zheng; 2006 Jul; 25(7):785-92. PubMed ID: 16831265
[TBL] [Abstract][Full Text] [Related]
5. Quantification of plasma Epstein-Barr virus DNA in patients with advanced nasopharyngeal carcinoma.
Lin JC; Wang WY; Chen KY; Wei YH; Liang WM; Jan JS; Jiang RS
N Engl J Med; 2004 Jun; 350(24):2461-70. PubMed ID: 15190138
[TBL] [Abstract][Full Text] [Related]
6. Role of Epstein-Barr virus DNA measurement in plasma in the clinical management of nasopharyngeal carcinoma in a low risk area.
Kalpoe JS; Dekker PB; van Krieken JH; Baatenburg de Jong RJ; Kroes AC
J Clin Pathol; 2006 May; 59(5):537-41. PubMed ID: 16489178
[TBL] [Abstract][Full Text] [Related]
7. Long-term prognostic effects of plasma epstein-barr virus DNA by minor groove binder-probe real-time quantitative PCR on nasopharyngeal carcinoma patients receiving concurrent chemoradiotherapy.
Lin JC; Wang WY; Liang WM; Chou HY; Jan JS; Jiang RS; Wang JY; Twu CW; Liang KL; Chao J; Shen WC
Int J Radiat Oncol Biol Phys; 2007 Aug; 68(5):1342-8. PubMed ID: 17449194
[TBL] [Abstract][Full Text] [Related]
8. Plasma Epstein-Barr virus DNA level strongly predicts survival in metastatic/recurrent nasopharyngeal carcinoma treated with palliative chemotherapy.
An X; Wang FH; Ding PR; Deng L; Jiang WQ; Zhang L; Shao JY; Li YH
Cancer; 2011 Aug; 117(16):3750-7. PubMed ID: 21319149
[TBL] [Abstract][Full Text] [Related]
9. [Quantitative analysis of plasma Epstein-Barr virus (EBV) DNA for monitoring of recurrence and metastasis in nasopharyngeal carcinoma patients after radiotherapy].
Li YH; Shao JY; Zhao MQ; Gao HY; Li LR; Guan ZZ; Zeng YX
Ai Zheng; 2003 Jun; 22(6):645-8. PubMed ID: 12948418
[TBL] [Abstract][Full Text] [Related]
10. Different prognostic values of plasma Epstein-Barr virus DNA and maximal standardized uptake value of 18F-FDG PET/CT for nasopharyngeal carcinoma patients with recurrence.
Shen T; Tang LQ; Luo DH; Chen QY; Li PJ; Mai DM; Guo SS; Liu LT; Qian CN; Guo X; Zeng MS; Mo HY; Mai HQ
PLoS One; 2015; 10(4):e0122756. PubMed ID: 25853677
[TBL] [Abstract][Full Text] [Related]
11. Pretherapy quantitative measurement of circulating Epstein-Barr virus DNA is predictive of posttherapy distant failure in patients with early-stage nasopharyngeal carcinoma of undifferentiated type.
Leung SF; Chan AT; Zee B; Ma B; Chan LY; Johnson PJ; Lo YM
Cancer; 2003 Jul; 98(2):288-91. PubMed ID: 12872347
[TBL] [Abstract][Full Text] [Related]
12. Prospective study of tailoring whole-body dual-modality [18F]fluorodeoxyglucose positron emission tomography/computed tomography with plasma Epstein-Barr virus DNA for detecting distant metastasis in endemic nasopharyngeal carcinoma at initial staging.
Tang LQ; Chen QY; Fan W; Liu H; Zhang L; Guo L; Luo DH; Huang PY; Zhang X; Lin XP; Mo YX; Liu LZ; Mo HY; Li J; Zou RH; Cao Y; Xiang YQ; Qiu F; Sun R; Chen MY; Hua YJ; Lv X; Wang L; Zhao C; Guo X; Cao KJ; Qian CN; Zeng MS; Mai HQ
J Clin Oncol; 2013 Aug; 31(23):2861-9. PubMed ID: 23857969
[TBL] [Abstract][Full Text] [Related]
13. Comparison of clinical and molecular surveillance in patients with advanced nasopharyngeal carcinoma after primary therapy: the potential role of quantitative analysis of circulating Epstein-Barr virus DNA.
Hong RL; Lin CY; Ting LL; Ko JY; Hsu MM
Cancer; 2004 Apr; 100(7):1429-37. PubMed ID: 15042677
[TBL] [Abstract][Full Text] [Related]
14. Quantitative analysis of plasma cell-free Epstein-Barr virus DNA in nasopharyngeal carcinoma after salvage nasopharyngectomy: a prospective study.
Wei WI; Yuen AP; Ng RW; Ho WK; Kwong DL; Sham JS
Head Neck; 2004 Oct; 26(10):878-83. PubMed ID: 15390201
[TBL] [Abstract][Full Text] [Related]
15. A comparison study of different PCR assays in measuring circulating plasma epstein-barr virus DNA levels in patients with nasopharyngeal carcinoma.
Le QT; Jones CD; Yau TK; Shirazi HA; Wong PH; Thomas EN; Patterson BK; Lee AW; Zehnder JL
Clin Cancer Res; 2005 Aug; 11(16):5700-7. PubMed ID: 16115906
[TBL] [Abstract][Full Text] [Related]
16. [Significance of cell-free Epstein-Barr virus DNA in monitoring prognosis of nasopharyngeal carcinoma].
Cao SM; Min HQ; Gao JS; Hong MH; Xiao XB; Zhang CQ; Liu XD; Zhang AL; Guo X
Ai Zheng; 2003 Mar; 22(3):302-6. PubMed ID: 12654192
[TBL] [Abstract][Full Text] [Related]
17. Relationship between pretreatment level of plasma Epstein-Barr virus DNA, tumor burden, and metabolic activity in advanced nasopharyngeal carcinoma.
Ma BB; King A; Lo YM; Yau YY; Zee B; Hui EP; Leung SF; Mo F; Kam MK; Ahuja A; Kwan WH; Chan AT
Int J Radiat Oncol Biol Phys; 2006 Nov; 66(3):714-20. PubMed ID: 17011447
[TBL] [Abstract][Full Text] [Related]
18. Quantitative and temporal correlation between circulating cell-free Epstein-Barr virus DNA and tumor recurrence in nasopharyngeal carcinoma.
Lo YM; Chan LY; Chan AT; Leung SF; Lo KW; Zhang J; Lee JC; Hjelm NM; Johnson PJ; Huang DP
Cancer Res; 1999 Nov; 59(21):5452-5. PubMed ID: 10554016
[TBL] [Abstract][Full Text] [Related]
19. Tumor heterogeneity measured on F-18 fluorodeoxyglucose positron emission tomography/computed tomography combined with plasma Epstein-Barr Virus load predicts prognosis in patients with primary nasopharyngeal carcinoma.
Chan SC; Chang KP; Fang YD; Tsang NM; Ng SH; Hsu CL; Liao CT; Yen TC
Laryngoscope; 2017 Jan; 127(1):E22-E28. PubMed ID: 27435352
[TBL] [Abstract][Full Text] [Related]
20. Early detection of nasopharyngeal carcinoma by plasma Epstein-Barr virus DNA analysis in a surveillance program.
Chan KC; Hung EC; Woo JK; Chan PK; Leung SF; Lai FP; Cheng AS; Yeung SW; Chan YW; Tsui TK; Kwok JS; King AD; Chan AT; van Hasselt AC; Lo YM
Cancer; 2013 May; 119(10):1838-44. PubMed ID: 23436393
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
